Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 15/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23572590 | 1.00 | IDO1 (0.56) | IDO1NPC1RAB9AKDM4EPKM | |
| SCHEMBL23271127 | 0.86 | IDO1 (0.56) | IDO1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29639827 | 0.86 | IDO1 (0.56) | IDO1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23271191 | 0.85 | IDO1 (0.60) | IDO1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL24118631 | 0.85 | IDO1 (0.64) | IDO1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21496334 | 0.85 | IDO1 (0.64) | IDO1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30055628 | 0.85 | IDO1 (0.64) | IDO1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29639861 | 0.85 | IDO1 (0.60) | IDO1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL23271123 | 0.82 | IDO1 (0.52) | IDO1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL23572599 | 0.82 | IDO1 (0.54) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352320-B2 | Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352320-B2 | Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, TPH1 | IDO1 1/4885NPC1 1298/4885RAB9A 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.